Wall Street brokerages forecast that Catabasis Pharmaceuticals Inc (NASDAQ:CATB) will announce earnings per share of ($0.62) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Catabasis Pharmaceuticals’ earnings. The highest EPS estimate is ($0.56) and the lowest is ($0.67). Catabasis Pharmaceuticals reported earnings per share of ($0.85) during the same quarter last year, which indicates a positive year over year growth rate of 27.1%. The company is scheduled to report its next earnings report on Thursday, March 12th.
On average, analysts expect that Catabasis Pharmaceuticals will report full-year earnings of ($2.42) per share for the current year, with EPS estimates ranging from ($2.47) to ($2.36). For the next financial year, analysts expect that the firm will report earnings of ($2.44) per share, with EPS estimates ranging from ($2.67) to ($2.21). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Catabasis Pharmaceuticals.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.07.
A number of analysts have issued reports on CATB shares. ValuEngine upgraded shares of Catabasis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Wedbush reiterated an “outperform” rating and issued a $18.00 price target on shares of Catabasis Pharmaceuticals in a report on Monday, July 29th. Finally, Citigroup reduced their price target on shares of Catabasis Pharmaceuticals from $72.00 to $60.00 in a report on Friday, November 8th.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its holdings in Catabasis Pharmaceuticals by 186.8% in the 2nd quarter. BlackRock Inc. now owns 172,679 shares of the biotechnology company’s stock valued at $1,393,000 after acquiring an additional 112,465 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Catabasis Pharmaceuticals by 74.7% in the 2nd quarter. Northern Trust Corp now owns 50,193 shares of the biotechnology company’s stock worth $405,000 after buying an additional 21,458 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Catabasis Pharmaceuticals by 16.0% in the 2nd quarter. Vanguard Group Inc. now owns 414,748 shares of the biotechnology company’s stock worth $3,347,000 after buying an additional 57,155 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Catabasis Pharmaceuticals by 321.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 43,406 shares of the biotechnology company’s stock worth $339,000 after buying an additional 33,106 shares during the last quarter. Finally, Wells Fargo & Company MN bought a new stake in shares of Catabasis Pharmaceuticals in the 2nd quarter worth about $82,000. Institutional investors own 37.72% of the company’s stock.
Shares of CATB traded down $0.19 on Monday, hitting $5.07. 54,000 shares of the stock traded hands, compared to its average volume of 70,590. The company has a market capitalization of $62.64 million, a PE ratio of -0.99 and a beta of 1.73. The business has a 50 day simple moving average of $5.04 and a 200 day simple moving average of $6.44. Catabasis Pharmaceuticals has a one year low of $3.60 and a one year high of $9.76.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD).
Featured Story: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.